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ABSTRACT
Profound alterations in host metabolism in lung cancer patients with
weight loss have been reported, including elevated phosphomonoesters
(PMEs) as detected by 31P magnetic resonance spectroscopy (MRS). In
healthy subjects, infusion of L-alanine induced significant increases in
hepatic PMEs and phosphodiesters (PDEs) due to rising concentrations of
3-phosphoglycerate and phosphoenolpyruvate, respectively. The aim of
the present study was to monitor these changes in the tumor-free liver of
lung cancer patients during L-alanine infusion by means of simultaneous
31P MRS and turnover measurements. Twenty-one lung cancer patients
without liver metastases with (CaWL) or without weight loss (CaWS), and
12 healthy control subjects were studied during an i.v. L-alanine challenge
of 1.4–2.8 mmol/kg followed by 2.8 mmol/kg/h for 90 min. Plasma L-
alanine concentrations increased during alanine infusion, from 0.35–0.37
mM at baseline to 5.37 6 0.14 mM in the CaWL patients, 6.67 6 0.51 mM
in the CaWS patients, and 8.47 6 0.88 mM in the controls (difference from
baseline and between groups during alanine infusion, all P < 0.001).
Glucose turnover and liver PME levels at baseline were significantly
elevated in the CaWL patients. Alanine infusion increased whole-body
glucose turnover by 8 6 3% in the CaWS patients (P 5 0.03), whereas no
significant change occurred in the CaWL and controls. PME levels in-
creased by 50 6 16% in controls (area under the curve, P < 0.01) and by
87 6 31% in the CaWS patients (P < 0.05) after 45–90 min. In contrast,
no significant changes in PME levels were observed in the CaWL patients.
Plasma insulin concentrations increased during L-alanine infusion in all
groups to levels that were lower in the CaWL patients than in the CaWS
patients and controls (P < 0.05). In lung cancer patients, but not in
controls, changes in PME and PDE levels during alanine infusion were
inversely correlated with their respective baseline levels (r 5 20.82 and
20.86, respectively; P < 0.001). In addition, changes in PMEs during
alanine infusion in lung cancer patients were inversely correlated with the
degree of weight loss (r 5 20.54; P < 0.05). This study demonstrates the
presence of major alterations in the pathway of hepatic gluconeogenesis in
weight-losing lung cancer patients, as shown by elevated glucose flux
before and during L-alanine infusion, and by the increased PME and PDE
levels, which reflect accumulation of gluconeogenic intermediates in these
patients. Weight-stable lung cancer patients show accelerated increases in
PME and PDE levels during L-alanine infusion, suggesting enhanced
induction of the gluconeogenic pathway. Our results suggest altered glu-
coneogenic enzyme activities and elevated alanine uptake within the livers
of weight-losing/weight-stable lung cancer patients.
INTRODUCTION
Weight loss in lung cancer is associated with both impaired therapy
outcome (1) and reduced survival (1–4). Characteristic features of
weight loss in lung cancer are breakdown of both fat mass and skeletal
muscle, whereas visceral organs typically are spared or even enlarged
(5, 6). Although profound alterations in host substrate metabolism in
cancer patients have been reported, mechanisms responsible for the
observed weight loss are as yet poorly understood. Isotope tracer
studies showed elevated protein breakdown and glucose turnover in
lung cancer patients (7–9). Increased gluconeogenesis from alanine
was observed in tumor-influenced hepatocytes (10), in tumor-bearing
animals in vivo (11), and in cancer patients with various tumor types
(12). We recently reported increased whole-body gluconeogenesis
from alanine in lung cancer patients with weight loss (13). A signif-
icant correlation between gluconeogenesis from alanine and the de-
gree of weight loss was also observed.
Because the liver is the main site for gluconeogenesis from alanine
(14), the observed increase in gluconeogenesis from alanine as ob-
served in weight-losing lung cancer patients is likely to be partly
related with altered liver metabolism (15, 16). In animal models,
altered hepatic enzyme activities (17, 18) and decreased liver phos-
phorylation status (19) and energy balance (18) were correlated with
tumor burden (20). Furthermore, elevated concentrations of gluconeo-
genic intermediates such as glucose-6-phosphate were observed
within the livers of these animals (18). Another experimental study
revealed altered hepatic metabolism in response to fructose infusion,
even in rats with minimal tumor burden (21). These alterations pre-
ceded the onset of cachexia, and it was suggested that they were
related to elevated hepatic gluconeogenesis in these animals.
Because of a lack of noninvasive techniques, data on altered liver
metabolism in humans with lung cancer are limited. In recent studies
using 31P MRS,3 elevated concentrations of PMEs were observed in
the livers of weight-losing cancer patients with various tumor types
(22) and lung cancer (23). In contrast, liver PME levels in weight-
stable cancer patients were not significantly different from those in
healthy subjects. Furthermore, hepatic PME levels were significantly
correlated with the rate of gluconeogenesis from alanine in lung
cancer patients, but not in healthy subjects (23). MRS studies have
also been used to obtain dynamic information on liver metabolism by
monitoring changes in hepatic metabolite concentrations during infu-
sion of a gluconeogenic substrate. Changes in PME and ATP levels
were reported in studies using 31P MRS with L-alanine infusion in
vivo in healthy rats (24) as well as in rats after ischemia (25) or
surgery (26). In healthy humans, 31P MRS with either a bolus (27) or
continuous (28) infusion of L-alanine has been shown to provide
information on changes in concentrations of gluconeogenic interme-
diates within the liver. However, information on liver gluconeogenic
intermediates during a metabolic challenge in lung cancer patients is
lacking.
The aims of the present study were to compare glucose metabolism
in the tumor-free livers of weight-losing and weight-stable lung can-
cer patients and healthy subjects by means of 31P MRS, with infusion
of L-alanine as a gluconeogenic substrate. Data were compared with
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flux measurements, using stable isotope tracers before/during alanine
infusion.
MATERIALS AND METHODS
Subjects. The study was approved by the Medical Ethics Committee of the
Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Patients with non-small cell lung cancer stage IIIA/B or IV (WHO grading
system) attending the outpatient department of the University Hospital Rot-
terdam, The Netherlands, were recruited. Patients who were in remission or
apparently cured were excluded. Additional exclusion criteria included liver
metastases (as checked for by computed tomography/ultrasound), metabolic
disease, corticosteroid treatment, elective surgery ,3 months prior to the
study, chemo- or radiotherapy ,4 weeks prior to the study, alcohol consump-
tion of .100 g/week (10 glasses), pregnancy, and extreme anorexia or artifi-
cial weight reduction by dieting. Healthy subjects without weight loss were
included as a control group. All participants signed informed consent.
Experimental Design. All subjects kept a dietary record during 7 days and
refrained from alcoholic drinks for 3 days prior to the MRS measurements.
Data on pre-illness stable weight, current weight, and weight loss over the
previous 6 months were taken from hospital records supplemented with oral
information from patients. The subjects were studied between 7:30 a.m. and
1:00 p.m. after an overnight fast (12–14 h). Body weight was measured to the
nearest 0.1 kg on an electrical weighing scale (Seca 707; Hamburg, Germany),
height was measured to the nearest 0.1 cm, and the thicknesses of four
skinfolds (triceps, biceps, subscapular, and supra iliac) were measured to the
nearest 0.2 mm, using a standard skinfold caliper (Holtain Ltd., London,
United Kingdom). A cannula (0.8 3 25 mm) was placed in the left cubital vein
for the infusion of the stable isotope tracer and unlabeled L-alanine. In the
contralateral cubital vein, an identical cannula was positioned for blood sam-
pling. To determine whole-body glucose turnover, a solution was prepared
containing [6,6-2H2]-D-glucose, 98 atom% (Mass Trace, Woburn, Massachu-
setts) in water, sterilized by autoclaving in glass vials. A solution of (unla-
beled) L-alanine in water (100 g/l; Bufa B.V., Uitgeest, The Netherlands) was
prepared, sterilized by autoclaving in glass bottles, and warmed to ;30°C.
The study consisted of two phases. During the first phase (baseline), a
priming dose of 0.03 mmol/kg of [6,6-2H2]-glucose was administered, fol-
lowed by a continuous infusion of 0.01 mmol/kg/h for 90 min. During the
second phase, a priming dose of 1.4–2.8 mmol/kg unlabeled L-alanine was
administered in 5–8 min, followed by a continuous infusion of 2.8 mmol/kg/h
L-alanine for 90 min to reobtain a steady state; simultaneously, the isotope
tracer infusion was continued. Venous blood samples were collected as fol-
lows: phase 1, one sample immediately before the isotope tracer infusion was
started (for determination of background enrichment of 2H-glucose) and at
10-min intervals from 30 to 90 min during isotope tracer infusion, after steady
state was reached; phase 2, at 15-min intervals during continuous L-alanine
infusion. Phosphorus MR spectra of the liver were obtained at baseline and at
3-min intervals during L-alanine infusion.
31P MRS of the Liver. Spectroscopy studies were performed with a
whole-body MR system equipped with a Helicon magnet operating at 2 T
(Vision Magneton; Siemens AG, Erlangen, Germany). A 16-cm diameter
transmit/receive 1H/31P surface coil was used for MR imaging localization,
shimming, and 31P MRS. Elastic bands were used for positioning the coil
lateral to the liver in the mid-axillary plane. Field homogeneity achieved in
shimming resulted in water peak line widths that were usually ,40 Hz (0.5
ppm). After an image of the region of interest was obtained, a one-dimensional
chemical shift imaging sequence was applied on a transverse slice of 4 cm
centered on the surface coil and the liver (1 3 4 phase-encoded matrix, field
of view 40 3 40 cm2), yielding volumes of 40 3 10 3 4 cm3 (29). Spectra
were collected with a 640-ms Hanning-sinc-shaped radio frequency pulse,
resulting in a flip angle of 135 degrees in the center of the coil, and 60 degrees
(weighted average) in the liver volume with a repetition time of 1 s (40
acquisitions).
Time domain data were Fourier transformed after gaussian multiplication
(center, 0 ms; width, 30 ms) and phase corrected. Quantification of spectral
peak areas was performed using a Numaris-3 software package (Siemens AG,
Erlangen, Germany), including polynomial baseline correction followed by
frequency domain curve fitting (30). Metabolite concentrations were calculated
from peak areas and expressed relative to total MR-detectable phosphate as
described previously (22). Total MR-detectable phosphate did not change
during L-alanine infusion (data not shown).
Substrate Concentrations and Glucose Turnover. Blood samples were
collected in tubes containing lithium heparin (Vacutainer; Becton Dickinson,
Meylan Cedex, France) and stored immediately on ice. After centrifugation (10
min, 1200 3 g, 4°C), the plasma was collected and stored at 220°C until
analysis. Blood glucose concentrations were measured enzymatically with a
glucose-oxidase/peroxidase assay system (Boehringer Mannheim, Mannheim,
Germany). Plasma alanine concentrations were determined enzymatically as
described by Williamson (31). Isotopic enrichment of deuterium-glucose (mole
percent excess) in plasma was determined by gas chromatography-mass spec-
trometry as described previously (13). Plasma concentrations of insulin and
glucagon were determined at two time points during baseline and two time
points during L-alanine infusion by radioimmunoassay techniques (Biosource,
Fleurus, Belgium, and Euro-Diagnostica, Sweden, respectively).
Statistical Analysis. Results are reported as means 6 SE. In each exper-
iment, the mean of five subsequent MR spectra was used as baseline value for
calculations. Mid-time points of MRS data acquisition at 15-min intervals
during L-alanine infusion (e.g., 7.5, 22.5, and 37.5 min) were used for graphical
representation, with values being expressed relative to the baseline value of
healthy control subjects (100%). As a measure of overall spectral response,
Table 1 Characteristicsa of study population
Control
(n 5 12)
Lung cancer group P
CaWS
(n 5 12)
CaWL
(n 5 9)
Cancer vs.
controls
CaWL vs.
CaWS
Age (years) 37–69b 38–76 53–81 ,0.01 0.20
Gender (M/F) 2/10 7/5 7/2
Disease stage (IIIA/IIIB/IV) 1/5/6 3/2/4
Previous therapy (n)c
Surgery 0 2 2
Radiotherapy 0 6 4
Chemotherapy 0 6 0
Weight (kg) 77.0 6 3.0 72.8 6 3.4 60.9 6 3.5 0.36 0.02
Weight change (kg) 0 1 6 1 29.0 6 1.4 0.56 ,0.001
Weight change (%) 0 1 6 1 212 6 2 0.59 ,0.001
% Ideal body weight 124 6 5 117 6 5 96 6 5 0.33 ,0.01
Body mass index (kg/m2) 25.8 6 1.0 25.1 6 1.0 20.9 6 1.1 0.62 0.01
Sum of skinfolds (mm)d 71 6 6 63 6 6 30 6 4 0.29 ,0.001
Albumin (g/l) 46 6 1e 43 6 1e 38 6 2e 0.34 ,0.01
Prealbumin (g/l) 0.30 6 0.01 0.29 6 0.01e 0.17 6 0.02e 0.47 ,0.001
a Mean 6 SE.
b Range.
c Antitumor treatment: surgery .3 months, or radio- and chemotherapy $4 weeks prior to the MRS study (number of patients).
d Sum of four skinfolds: biceps, triceps, supra iliac, subscapular (mm).
e One value missing.
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integrals of time-response curves (AUC) of peak areas over the 0–45, 45–90,
and 0–90 min intervals during L-alanine infusion were calculated and ex-
pressed relative to the baseline values. Between-group differences in baseline
values and response to alanine infusion were analyzed using ANOVA.
Changes from baseline values were analyzed using Student’s paired t test.
Differences between groups were analyzed by multiple regression analysis,
using age, gender, and priming dose of L-alanine as covariates. Pearson’s
correlation coefficients were calculated between baseline metabolite concen-
trations (expressed relative to total MR-detectable phosphate) and absolute
metabolite change (AUC) per minute during L-alanine infusion. Statistical
significance was set at P , 0.05.
RESULTS
Study Population. Twenty-one patients with non-small cell lung
cancer were included in the study: 9 weight-losing ($5% weight loss;
CaWL patients) and 12 weight-stable patients (,5% weight loss;
CaWS patients). Twelve healthy subjects were included as controls.
Characteristics of the study population are listed in Table 1. The mean
age of the lung cancer patients was higher than in controls, although
age ranges largely overlapped. The disease stage was similar in the
CaWL and CaWS patients. The previous antitumor treatment was also
comparable in both groups, except for chemotherapy, which had been
given as a previous treatment in six CaWS patients but in none of the
CaWL patients. Note that none of the patients received any antitumor
therapy at the time of the study. The CaWL patients had lost 9.0 6 1.4
kg (mean 6 SE) or 12% (range, 6–22%) of their pre-illness stable
body weight within the 6 months preceding the study. Body weight,
body mass index, and sum of skinfolds were significantly lower in the
CaWL patients compared with the CaWS patients and controls
(P , 0.05). Albumin and prealbumin levels were also significantly
decreased in CaWL patients. Liver function tests were normal in all
subjects. All patients had a history of smoking, compared with 42% of
the healthy subjects. Thirty-eight percent of the CaWL patients, 33%
of the CaWS patients, and 33% of healthy control subjects were actual
smokers at the time of study. No differences in energy intake were
detected between any of the groups. Because of the differences in age
and gender between the groups, all data were checked for potential
confounding by age or gender. Although in no case significant was
confounding by age nor gender observed, all presented statistical
analyses are adjusted for age and gender.
Plasma Substrate Concentrations and Flux Measurements.
Fasting blood glucose levels were similar in lung cancer patients
(CaWL patients, 5.8 6 0.3 mM; CaWS patients, 5.3 6 0.2 mM) and
healthy subjects (5.7 6 0.2 mM) and did not change during L-alanine
infusion (CaWL patients, 5.7 6 0.4 mM; CaWS patients, 5.0 6 0.1
mM; controls, 5.5 6 0.2 mM). Baseline plasma alanine concentrations
were similar between lung cancer patients and healthy controls (0.35–
0.37 mM). L-Alanine infusion caused a sharp and highly significant
rise in plasma alanine concentrations to a mean of 5.37 6 0.14 mM in
the CaWL patients, 6.67 6 0.51 mM in the CaWS patients, and
8.47 6 0.88 mM in the controls (CaWL versus CaWS and CaWS
versus controls, P , 0.001). These postalanine plasma concentrations
were significantly different between all groups (P , 0.001). Turnover
rates of glucose at baseline and during L-alanine infusion are pre-
sented in Fig. 1. Whole-body glucose turnover at baseline was 35%
higher in the CaWL patients compared with both the CaWS patients
and controls (P , 0.01). Although during alanine infusion values of
glucose turnover appeared to increase in all groups, this was only
statistically significant in the CaWS group (0.05 6 0.02 mmol/kg/h;
P , 0.05). Glucose turnover during alanine infusion was still 36%
higher in CaWL patients than in CaWS patients and controls
(P , 0.05).
Hepatic Concentrations of Gluconeogenic Intermediates. Base-
line PMEs were significantly elevated in CaWL patients
(10.5 6 1.0%) compared with CaWS patients and controls
(6.7 6 0.5% and 7.9 6 0.7%, respectively; P , 0.01, corrected for
Fig. 1. Whole-body rate of appearance (turnover) of glucose before and during
primed-continuous L-alanine infusion in healthy control subjects (Control; n 5 10) and
weight-stable (CaWS; n 5 12) and weight-losing (CaWL; n 5 6) lung cancer patients.
Turnover rates were assessed using a primed-constant infusion of [6,6-2H2]-glucose.
Results are presented as means (columns); bars, SE. Results for CaWL patients were
significantly different from CaWS patients and controls: p, P , 0.05; pp, P , 0.01
(ANOVA, adjusted for age and gender). #, significantly different from baseline: P , 0.05
(paired t test).
Fig. 2. PME (A) and PDE (B) concentrations in the livers of healthy control subjects
(E; n 5 9) as well as weight-stable (F; n 5 10) and weight-losing (; n 5 7) lung cancer
patients during a primed-constant infusion of L-alanine (initial priming, 1.4–2.8 mmol/kg;
infusion, 2.8 mmol/kg/h). Curves represent means; bars, SE. Baseline values are means of
five spectra acquired in each subject before L-alanine infusion. Values are expressed as
percentage of mean baseline value of healthy subjects (100%). Times during L-alanine
infusion are mid-time points of 31P MRS data collection referenced to the start of the
L-alanine infusion (0 5 baseline).
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age), as reported previously. No differences in PDEs (CaWL group,
30.6 6 1.9%; CaWS group, 27.8 6 2.2%; controls, 31.4 6 2.0%)
were observed between the groups.
In Fig. 2, changes in hepatic metabolite concentrations during
L-alanine infusion are shown. PMEs increased gradually in the
controls and reached statistical significance at 60 min (P , 0.01).
In CaWS patients, PMEs showed a sharp and highly significant rise
during the first 30 min and were still significantly elevated at 75
min of L-alanine infusion (P , 0.05). The slope of the PME
concentration from 0 to 30 min was significantly steeper in CaWS
patients than in controls (2.48 6 0.50%/min versus 0.77 6 0.45%/
min; P 5 0.01). In contrast, PME concentrations in CaWL patients
did not change significantly during alanine infusion. PDEs initially
decreased in controls but increased in both CaWS and CaWL
patients, with significantly different slopes for the PDE curves
between 0 and 30 min for the CaWL and CaWS patients versus
healthy subjects (0.62 6 0.33%/min and 1.20 6 0.77%/min versus
20.57 6 0.33%/min, respectively; P 5 0.02). PDE levels as such
were not significantly different from baseline at any time point in
any of the three groups.
Overall Changes during L-Alanine Infusion: AUC. Overall
changes in metabolite concentrations during L-alanine infusion rela-
tive to baseline are presented in Table 2. During the first 45 min of
alanine infusion, the increase in PME concentrations was significantly
less in CaWL patients than in CaWS patients and controls (P 5 0.02).
At 45–90 min of alanine infusion, this difference in response between
the CaWL and CaWS patients and controls remained, although it was
no longer statistically significant.
Hormone Levels. Plasma insulin and glucagon levels are pre-
sented in Fig. 3. Baseline insulin concentrations were lower in CaWL
patients than in the CaWS patients and controls (P , 0.05). Insulin
levels showed a strong increase at 45 min of L-alanine infusion
(P , 0.01) and were still significantly elevated from baseline at 90
min in all groups (P , 0.01). In CaWL patients, insulin levels
remained significantly lower than in both the CaWS and control
groups during the 90 min of alanine infusion (P , 0.01). Baseline
glucagon levels were similar in all groups. L-Alanine infusion caused
a substantial rise in plasma glucagon at 45–90 min in all groups
(P , 0.01). No significant differences in glucagon concentrations
during alanine infusion were observed between any of the groups.
Correlations. Spectral changes in PMEs and PDEs during alanine
infusion were strongly dependent on their respective baseline concen-
trations in lung cancer patients (r 5 20.82 and 20.86, respectively;
P , 0.001) but not in controls (r 5 20.07 and 20.30, respectively;
Fig. 4). Furthermore, patients with a higher degree of weight loss
showed smaller increases in PME levels during alanine infusion
(r 5 20.54; P , 0.05).
DISCUSSION
In the present study, hepatic gluconeogenesis from alanine in lung
cancer patients was monitored by means of 31P MRS during an i.v.
L-alanine challenge, and information on gluconeogenic intermediates
was obtained noninvasively. Simultaneously, glucose turnover before
and during L-alanine infusion was measured using stable isotope
tracers.
Glucose flux was significantly elevated in CaWL patients at base-
line compared with CaWS patients and control subjects, confirming
other studies (7, 13). Changes in glucose turnover during L-alanine
infusion were minimal, as could be expected in view of the autoreg-
ulatory mechanisms that control hepatic glucose output (32–34). Liver
PME levels increased during alanine infusion in both CaWS patients
and controls, confirming studies performed in healthy animals (24)
Fig. 3. Plasma insulin (A) and glucagon (B) concentrations in healthy control subjects
(E; n 5 10), weight-stable (F; n 5 10) and weight-losing (; n 5 6) lung cancer patients
before and during a primed-constant infusion of L-alanine (initial priming, 1.4–2.8
mmol/kg; infusion, 2.8 mmol/kg/h). Curves represent means; bars, SE.
Table 2 Hepatic phosphorus metabolite levelsa after primed-constant infusion of L-alanine in healthy control subjects and lung cancer patients
Time of alanine
infusion
Control
(n 5 9)
Lung cancer Pb
CaWS
(n 5 10)
CaWL
(n 5 7)
Cancer vs.
controls
CaWL vs.
CaWS
PME 0–45 min 21 6 9 58 6 14c 7 6 8 0.31 0.02
45–90 min 50 6 16c 87 6 31d 7 6 9 0.55 0.22
0–90 min 33 6 11d 69 6 19c 11 6 10 0.35 0.28
PDE 0–45 min 25 6 7 32 6 20 23 6 15 0.56 0.23
45–90 min 23 6 10 40 6 33 9 6 12 0.49 0.24
0–90 min 28 6 5 30 6 22 12 6 11 0.46 0.32
a Area under the curve during L-alanine infusion expressed as change from baseline (%, mean 6 SE).
b For between-group differences in response to alanine infusion adjusted for age, gender, and L-alanine prime dose.
c,d Difference from baseline values (Student’s paired t test): c P , 0.01; d P , 0.05.
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and humans (27, 28), in which this rise in PMEs was attributed to
increased concentrations of 3PG (24, 27). Our finding in the present
study that in CaWS patients, PMEs increased significantly faster and
reached levels twice as high as in healthy subjects may reflect a more
rapid rise in concentrations of 3PG in the livers of these patients. In
contrast, in CaWL patients, PME levels were already elevated at
baseline and did not increase any further during alanine infusion.
Moreover, a strong negative correlation between baseline PME levels
and the increase in PMEs during alanine infusion was observed in
lung cancer patients, but not in healthy controls, suggesting that the
3PG levels in CaWL patients were maximal at baseline and could not
be increased any further by an i.v. alanine challenge.
Although mean PDE concentrations were similar in lung cancer
patients and healthy controls both at baseline and during alanine
infusion, a significant difference in slope between patients (increase)
and healthy subjects (decrease) was detected in the first 30 min of
alanine infusion. As for PMEs, changes in PDEs during alanine
infusion were negatively correlated with baseline PDE levels in lung
cancer patients but not in healthy subjects. The PDE resonance con-
tains components of phospholipid membranes, such as glycerophos-
phorylethanolamine and glycerophosphorylcholine, and the gluconeo-
genic intermediate, phosphoenolpyruvate (35). In liver extracts of
healthy rats, post-alanine infusion phosphoenolpyruvate concentra-
tions were significantly elevated (24, 27), suggesting that the increase
in PDE in lung cancer patients observed in the present study is most
likely due to elevated accumulation of phosphoenolpyruvate.
The mechanisms involved in the increasing levels of PME before
and during alanine infusion in lung cancer patients could be enhanced
uptake of alanine within the hepatocytes and/or elevated gluconeo-
genic enzyme activity. In animal studies in vivo, alanine concentra-
tions in the livers of tumor-bearing hosts were elevated (36), whereas
plasma alanine concentrations were decreased (37), suggesting ele-
vated uptake of alanine by the liver. Some authors reported reduced
plasma alanine concentrations in weight-losing lung cancer patients
(38, 39). In the present study, we did not detect any differences in
baseline plasma alanine levels between the two groups of lung cancer
patients and healthy subjects. This indicates that the elevated alanine
flux reported previously in weight-losing lung cancer patients (13) is
counterbalanced by increased alanine uptake in the liver, resulting in
similar plasma levels in CaWL and CaWS patients, and controls. It is
noteworthy that although plasma alanine concentrations increased
significantly in all groups during infusion of L-alanine, they did not
increase to the same extent in all groups, but in the order
CaWL , CaWS , controls (P , 0.001). Because all statistical
analyses were adjusted for alanine priming dose, these differences
were not explained by the alanine priming dose. This would imply that
alanine uptake by the liver during alanine infusion is increased in lung
cancer patients, especially in weight-losing patients.
Elevated activities of gluconeogenic key enzymes in the livers of
tumor-bearing hosts have been reported by several authors, which
could explain the elevated PME levels in CaWL patients at baseline,
as well as the faster and larger increase in PMEs observed in CaWS
patients during alanine infusion. Increased PDE and PME levels
during alanine infusion, most likely reflecting elevated phosphoenol-
pyruvate and 3PG concentrations, could be explained by enhanced
activities of pyruvate carboxylase (converting pyruvate into oxaloac-
etate) and/or phosphoenolpyruvate carboxykinase (converting oxalo-
acetate into phosphoenolpyruvate). The observed increase in glucose
production could also be the result of enhanced glucose-6-phospha-
tase activity. Indeed, animal studies showed elevated activities of
pyruvate carboxylase in the livers of rats bearing mammary adeno-
carcinomas (40), and phosphoenolpyruvate carboxykinase (41) and
glucose-6-phosphatase (42) in the livers of sarcoma-bearing rats.
Factors that may be involved in the enhanced activities of gluconeo-
genic enzymes are decreased insulin or increased glucagon concen-
trations (37, 43, 44), which would stimulate gluconeogenic key en-
Fig. 4. Changes in PME (A) and PDE (B) con-
centrations in the livers of healthy control subjects
(n 5 9) and lung cancer patients (n 5 17) during a
primed-constant infusion of L-alanine. Changes
plotted against respective baseline values, expressed
relative to total MR-detectable phosphate (%). r,
Pearson’s correlation coefficient.
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zymes (45). Relatively higher glucagon:insulin ratios were observed
in CaWL patients compared with CaWS patients.
In summary, this study demonstrates the presence of major alterations
in gluconeogenesis in the tumor-free livers of lung cancer patients both
with and without weight loss. Weight-losing lung cancer patients have
markedly elevated glucose flux before as well as during L-alanine infu-
sion. This is also confirmed by elevated PME and PDE levels within the
liver, which reflect accumulation of gluconeogenic intermediates in these
patients both before and during alanine infusion. Neither glucose flux nor
the concentrations of gluconeogenic intermediates within the liver
showed any change during alanine infusion in weight-losing cancer
patients, suggesting that gluconeogenesis is already maximally induced at
baseline in these patients. Weight-stable lung cancer patients, having a
normal glucose flux, showed an accelerated rise in PME and PDE levels
during L-alanine infusion. Our results suggest that both altered gluconeo-
genic enzyme activities within the liver and elevated alanine uptake are
involved in these abnormalities.
ACKNOWLEDGMENTS
We thank C. H. K. Hordijk-Luijk and J. D. L. Wattimena for performing
biochemical analyses and mass spectrometry, and H. J. Agteresch, C. C. M.
Bartels, M. Heijsteeg, F. Lagerwaard, A. S. T. Planting, M. J. M. van Mierlo,
S. Senan, R. Slingerland, G. Stoter, M. M. A. Tilanus-Linthorst, J. Verweij,
and A. G. Zwanenburg for cooperation in the patient recruitment. We also
thank W. Schneijderberg and C. Onna for assistance during the experiments.
REFERENCES
1. Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R.,
Cohen, M. H., Douglass, H., Jr., Engstrom, P. F., Ezdinli, E. Z., Horton, J., Johnson,
G. J., Moertel, C. G., and Oken, M. M. Prognostic effect of weight loss prior to
chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med.,
69: 491–497, 1980.
2. Stanley, K. E. Prognostic factors for survival in patients with inoperable lung cancer.
J. Natl. Cancer Inst., 65: 25–32, 1980.
3. Costa, G., Lane, W. W., Vincent, R. G., Siebold, J. A., Aragon, M., and Bewley, P. T.
Weight loss and cachexia in lung cancer. Nutr. Cancer, 2: 98–103, 1980.
4. Chute, C. G., Greenberg, E. R., Baron, J., Korson, R., Baker, J., and Yates, J.
Presenting conditions of 1539 population-based lung cancer patients by cell type and
stage in New Hampshire and Vermont. Cancer (Phila.), 56: 2107–2111, 1985.
5. Cohn, S. H., Gartenhaus, W., Sawitsky, A., Rai, K., Zanzi, I., Vaswani, A., Ellis,
K. J., Yasumura, S., Cortes, E., and Vartsky, D. Compartmental body composition of
cancer patients by measurement of total body nitrogen, potassium, and water. Me-
tabolism, 30: 222–229, 1981.
6. Heymsfield, S. B., and McManus, C. B. Tissue components of weight loss in cancer
patients. A new method of study and preliminary observations. Cancer (Phila.), 55:
238–249, 1985.
7. Heber, D., Chlebowski, R. T., Ishibashi, D. E., Herrold, J. N., and Block, J. B.
Abnormalities in glucose and protein metabolism in noncachectic lung cancer pa-
tients. Cancer Res., 42: 4815–4819, 1982.
8. Melville, S., McNurlan, M. A., Calder, A. G., and Garlick, P. J. Increased protein
turnover despite normal energy metabolism and responses to feeding in patients with
lung cancer. Cancer Res., 50: 1125–1131, 1990.
9. Richards, E. W., Long, C. L., Nelson, K. M., Tohver, O. K., Pinkston, J. A., Navari,
R. M., and Blakemore, W. S. Protein turnover in advanced lung cancer patients.
Metabolism, 42: 291–296, 1993.
10. Roh, M. S., Ekman, L., Jeevanandam, M., and Brennan, M. F. Gluconeogenesis in
tumor-influenced hepatocytes. Surgery, 96: 427–434, 1984.
11. Lowry, S. F., Foster, D. M., Norton, J. A., Berman, M., and Brennan, M. F. Glucose
disposal and gluconeogenesis from alanine in tumor-bearing Fischer 344 rats. J. Natl.
Cancer Inst., 66: 653–658, 1981.
12. Waterhouse, C., Jeanpretre, N., and Keilson, J. Gluconeogenesis from alanine in
patients with progressive malignant disease. Cancer Res., 39: 1968–1972, 1979.
13. Leij-Halfwerk, S., Dagnelie, P. C., van den Berg, J. W. O., Wattimena, J. D. L.,
Hordijk-Luijk, C. H., and Wilson, J. H. P. Weight loss and elevated gluconeogenesis
from alanine in lung cancer patients. Am. J. Clin. Nutr., in press, 2000.
14. Stumvoll, M., Meyer, C., Perriello, G., Kreider, M., Welle, S., and Gerich, J. Human
kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am. J.
Physiol., 274: E817–E826, 1998.
15. Kern, K. A., and Norton, J. A. Cancer cachexia. Jpn. J. Parenter. Enteral Nutr., 12:
286–298, 1988.
16. Brauer, M., Inculet, R. I., Bhatnagar, G., Marsh, G. D., Driedger, A. A., and
Thompson, R. T. Insulin protects against hepatic bioenergetic deterioration induced
by cancer cachexia: an in vivo 31P magnetic resonance spectroscopy study. Cancer
Res., 54: 6383–6386, 1994.
17. Herzfeld, A., and Greengard, O. The effect of lymphoma and other neoplasms on
hepatic and plasma enzymes of the host rat. Cancer Res., 37: 231–238, 1977.
18. Argiles, J. M., and Lopez-Soriano, F. J. The energy state of tumor-bearing rats.
J. Biol. Chem., 266: 2978–2982, 1991.
19. Dagnelie, P. C., Bell, J. D., Williams, S. C., Bates, T. E., Abel, P. D., and Foster, C. S.
Altered phosphorylation status, phospholipid metabolism and gluconeogenesis in the
host liver of rats with prostate cancer: a 31P magnetic resonance spectroscopy study.
Br. J. Cancer, 67: 1303–1309, 1993.
20. Schneeberger, A. L., Thompson, R. T., Driedger, A. A., Finley, R. J., and Inculet, R. I.
Effect of cancer on the in vivo energy state of rat liver and skeletal muscle. Cancer
Res., 49: 1160–1164, 1989.
21. Gehman, K. E., Inculet, R. I., Brauer, M., Marsh, G. D., Driedger, A. A., and
Thompson, R. T. Early detection of cancer cachexia in the rat using 31P magnetic
resonance spectroscopy of the liver and a fructose stress test. NMR Biomed., 9:
271–275, 1996.
22. Dagnelie, P. C., Sijens, P. E., Kraus, D. J. A., van Dijk, P., van den Berg, J. W. O.,
Planting, A., Oudkerk, M., and Wilson, J. Abnormal liver metabolism in cancer
patients detected by 31P MR spectroscopy. NMR Biomed., in press, 2000.
23. Leij-Halfwerk, S., Dagnelie, P. C., van den Berg, J. W. O., and Sijens, P. E. Hepatic
sugar phosphate levels and rate of gluconeogenesis in lung cancer: simultaneous
turnover measurements and 31P magnetic resonance spectroscopy in vivo. Clin. Sci.
(Lond.), in press, 2000.
24. Changani, K. K., Barnard, M. L., Bell, J. D., Thomas, E. L., Williams, S. C., Bloom,
S. R., and Iles, R. A. In vivo assessment of metabolic perturbations following alanine
and glucagon administration using 31P-MRS in the rat. Biochim. Biophys. Acta,
1335: 290–304, 1997.
25. Morikawa, S., Inubushi, T., Takahashi, K., Shigemori, S., and Ishii, H. Relationship
between gluconeogenesis and phosphoenergetics in rat liver assessed by in vivo 13C
and 31P NMR spectroscopy. NMR Biomed., 10: 18–24, 1997.
26. Stromski, M. E., Arias-Mendoza, F., Alger, J. R., and Shulman, R. G. Hepatic
gluconeogenesis from alanine: 13C nuclear magnetic resonance methodology for in
vivo studies. Magn. Reson. Med., 3: 24–32, 1986.
27. Dagnelie, P. C., Menon, D. K., Cox, I. J., Bell, J. D., Sargentoni, J., Coutts, G. A.,
Urenjak, J., and Iles, R. A. Effect of L-alanine infusion on 31P nuclear magnetic
resonance spectra of normal human liver: towards biochemical pathology in vivo.
Clin. Sci., 83: 183–190, 1992.
28. Ross, B. D. Acid-base regulation: has 31P NMR any answers? Contrib. Nephrol., 63:
53–59, 1988.
29. Sijens, P. E., Van Dijk, P., Dagnelie, P. C., and Oudkerk, M. Non-T1-weighted 31P
chemical shift imaging of the human liver. Magn. Reson. Imaging, 13: 621–628,
1995.
30. Sijens, P. E., Dagnelie, P. C., Halfwerk, S., van Dijk, P., Wicklow, K., and Oudkerk,
M. Understanding the discrepancies between 31P MR spectroscopy assessed liver
metabolite concentrations from different institutions. Magn. Reson. Imaging, 16:
205–211, 1998.
31. Williamson, D. H. L-Alanin; Bestimmung mit Alanin-Dehydrogenase. In: H. U.
Bergmeyer (ed.), Methoden der Enzymatischen Analyse., Vol. 2, pp. 1634–1637.
Weinheim, Germany: Verlag Chemie, 1970.
32. Wolfe, R. R., Jahoor, F., and Shaw, J. H. Effect of alanine infusion on glucose and
urea production in man. Jpn. J. Parenter. Enteral Nutr., 11: 109–111, 1987.
33. Diamond, M. P., Rollings, R. C., Steiner, K. E., Williams, P. E., Lacy, W. W., and
Cherrington, A. D. Effect of alanine concentration independent of changes in insulin
and glucagon on alanine and glucose homeostasis in the conscious dog. Metabolism,
37: 28–33, 1988.
34. Jenssen, T., Nurjhan, N., Consoli, A., and Gerich, J. E. Failure of substrate-induced
gluconeogenesis to increase overall glucose appearance in normal humans. Demon-
stration of hepatic autoregulation without a change in plasma glucose concentration.
J. Clin. Investig., 86: 489–497, 1990.
35. Meyerhoff, D. J., Karczmar, G. S., and Weiner, M. W. Abnormalities of the liver
evaluated by 31P MRS. Investig. Radiol., 24: 980–984, 1989.
36. Rivera, S., Azcon-Bieto, J., Lopez-Soriano, F. J., Miralpeix, M., and Argiles, J. M.
Amino acid metabolism in tumour-bearing mice. Biochem. J., 249: 443–449, 1988.
37. Inculet, R. I., Peacock, J. L., Gorschboth, C. M., and Norton, J. A. Gluconeogenesis
in the tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin,
and glucagon. J. Natl. Cancer Inst., 79: 1039–1046, 1987.
38. Heber, D., Byerly, L. O., and Chlebowski, R. T. Metabolic abnormalities in the cancer
patient. Cancer (Phila.), 55: 225–229, 1985.
39. Cascino, A., Muscaritoli, M., Cangiano, C., Conversano, L., Laviano, A., Ariemma,
S., Meguid, M. M., and Rossi Fanelli, F. Plasma amino acid imbalance in patients
with lung and breast cancer. Anticancer Res., 15: 507–510, 1995.
40. Liu, K. J., Kleps, R., Henderson, T., and Nyhus, L. 13C NMR study of hepatic
pyruvate carboxylase activity in tumor rats. Biochem. Biophys. Res. Commun., 179:
366–371, 1991.
41. Noguchi, Y., Vydelingum, N. A., and Brennan, M. F. The reversal of increased
gluconeogenesis in the tumor-bearing rat by tumor removal and food intake. Surgery,
106: 423–430, 1989.
42. Gutman, A., Thilo, E., and Biran, S. Enzymes of gluconeogenesis in tumor-bearing
rats. Isr. J. Med. Sci., 5: 998–1001, 1969.
43. Rofe, A. M., Bourgeois, C. S., Coyle, P., Taylor, A., and Abdi, E. A. Altered insulin
response to glucose in weight-losing cancer patients. Anticancer Res., 14: 647–650,
1994.
44. Bartlett, D. L., Charland, S. L., and Torosian, M. H. Reversal of tumor-associated
hyperglucagonemia as treatment for cancer cachexia. Surgery, 118: 87–97, 1995.
45. O’Riordan, J. L. H. O., Malan, P. G., and Gould, R. P. Essentials of Endocrinology,
ed. 2. Oxford: Blackwell Scientific Publications, 1988.
623
HEPATIC GLUCONEOGENESIS IN LUNG CANCER AND 31P MRS
